AI-Driven Diabetic Retinopathy Screening Market (2025 to 2035)

AI-Driven Diabetic Retinopathy Screening Market Summary:

The global AI-driven diabetic retinopathy screening market size was valued at USD 455 million in 2025 and is projected to reach USD 1,510 million by 2035, expanding at a CAGR of 12.80% from 2026 to 2035. Market growth is supported by the escalating global burden of diabetes mellitus, rapid deployment of deep learning-based fundus image analysis platforms, and increasing adoption of automated, point-of-care ophthalmic screening tools in both high-income and resource-limited settings.

AI-Driven Diabetic Retinopathy Screening Market Revenue Forecast, 2022–2035 (US$ Million)

Key Market Takeaways & Insights

• North America AI-driven diabetic retinopathy screening market held the largest share of 35.80% of the global market in 2025.
• The AI-driven diabetic retinopathy screening industry in the Asia Pacific is expected to grow significantly 10.70 over the forecast period due to large diabetic populations in India and China.
• By technology, the deep learning & convolutional neural networks (CNN) segment held the largest market share of 62.00% in 2025.
• By disease severity, the moderate non-proliferative diabetic retinopathy (NPDR) segment held the largest market share of 27.00% in 2025.
• By end use, the hospital & ophthalmology clinics segment held the largest market share of 38.00% in 2025.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 AI-Driven Diabetic Retinopathy Screening Market Size: USD 455 Million
• 2035 AI-Driven Diabetic Retinopathy Screening Market Size: USD 1,510 Million
• CAGR (2026-2035): 12.80%

AI-Driven Diabetic Retinopathy Screening Market Regional Forecast Analysis, 2026–2035 (US$ Million)

Disease Epidemiology Analysis:

• Prevalence & incidence trends
• Patient population analysis
• Demographic burden assessment
• Regional disease distribution

Treatment Landscape Overview:

• Standard of care analysis
• Current treatment pathways
• Unmet medical needs
• Comparative therapy positioning

AI-Driven Diabetic Retinopathy Screening Market Outlook Analysis Conservative, Likely, Optimistic, (US$ Million), 2025–2035

Market Dynamics:

Market Drivers:

Worldwide Increase in Diabetes Prevalence

The worldwide rise in diabetes prevalence is significantly driving demand for AI-driven diabetic retinopathy screening solutions, as early and accurate detection of retinal damage remains critical for preventing blindness and irreversible vision loss. AI-enabled fundus image analysis and deep learning algorithms enable rapid, cost-effective screening of large diabetic populations without requiring a specialist ophthalmologist at the point of care. The increasing incidence of diabetes has substantially increased the number of annual ophthalmic screening requirements globally. According to the International Diabetes Federation (IDF) Diabetes Atlas 2023, there were approximately 537 million adults living with diabetes worldwide in 2023, with projections indicating this number will rise to 643 million by 2030 and 783 million by 2045. Diabetic retinopathy is estimated to affect approximately one-third of all people with diabetes, making it the leading cause of preventable blindness among working-age adults.

Advancement in Deep Learning and AI Regulatory Approvals

The growing regulatory clearance of AI-based diabetic retinopathy screening platforms is further accelerating market adoption globally. Landmark approvals such as the FDA's clearance of IDx-DR as the first autonomous AI diagnostic system for diabetic retinopathy detection without the need for a specialist clinician have opened the pathway for broad clinical deployment. Subsequent approvals across the EU (CE marking), India (CDSCO), and other major markets are expanding the addressable commercial landscape for AI screening vendors. The growing integration of AI screening tools within national diabetic eye screening programs in countries such as the United Kingdom, Singapore, and Thailand further validates the clinical utility and cost-effectiveness of these platforms. Furthermore, increasing investments in deep learning model development, retinal fundus photography hardware innovation, and cloud-based teleophthalmology platforms are expected to sustain demand for advanced AI-driven screening solutions throughout the forecast period.

Market Restraint:

Data Privacy Concerns and Algorithmic Bias

The AI-driven diabetic retinopathy screening industry faces significant challenges related to data privacy, algorithmic transparency, and performance variability across diverse patient populations. AI models trained on datasets from specific ethnic groups or imaging systems may exhibit reduced sensitivity and specificity when deployed across different demographic and clinical settings, raising concerns about diagnostic equity. Healthcare providers and regulatory authorities require comprehensive real-world validation studies demonstrating consistent performance across diverse racial, ethnic, and clinical contexts before approving broad clinical deployment of AI screening systems. Additionally, the collection, storage, and cross-border transmission of sensitive ophthalmic imaging data are subject to stringent data protection regulations, including the GDPR in Europe and HIPAA in the United States, creating compliance complexity for global platform vendors.

Reimbursement Gaps and Integration Challenges

Furthermore, inconsistent reimbursement frameworks for AI-assisted diagnostic services across national healthcare systems represent a significant barrier to market adoption. Many payers have not yet established dedicated reimbursement codes for autonomous AI screening solutions, limiting the commercial viability of deployment at scale in primary care and community health settings. The integration of AI screening platforms with heterogeneous electronic health record (EHR) systems, fundus camera hardware from multiple manufacturers, and existing ophthalmology workflows also requires significant technical investment and customization. These factors can delay implementation timelines, increase deployment costs, and restrict adoption particularly in price-sensitive healthcare markets in developing economies.

Market Opportunities:

Expansion into Primary Care and Telemedicine Screening Programs

The increasing integration of AI-driven diabetic retinopathy screening within primary care settings and national telemedicine programs is creating substantial growth opportunities for market participants. Healthcare systems across high-burden regions are increasingly deploying AI screening platforms at the point-of-care within general practice clinics, community health centers, and diabetes management programs to eliminate the need for referral to specialist ophthalmology services. This expansion significantly increases the addressable screening population and supports early detection at scale. In addition, growing investments in mobile fundus camera technology, portable AI-integrated imaging devices, and cloud-based diagnostic platforms are making AI-driven retinopathy screening accessible in rural and underserved communities. For instance, in March 2025, Google Health announced the expansion of its Automated Retinal Disease Assessment (ARDA) AI system across community health programs in South Asia and Sub-Saharan Africa through partnerships with local healthcare ministries, demonstrating the growing commercial focus on deploying AI screening at population scale.

The growing adoption of wearable ocular imaging technologies and smartphone-based fundus photography combined with AI analysis is further creating significant market opportunities by reducing hardware cost barriers to screening program deployment. AI platforms capable of simultaneous detection of multiple diabetic complications, including macular edema and glaucomatous changes, alongside retinopathy grading, are expected to deliver greater clinical value and support broader market adoption. Furthermore, increasing healthcare digitalization across emerging economies, expanding national diabetes registries, and rising awareness of preventable blindness are expected to support the uptake of AI-driven ophthalmic screening solutions throughout the forecast period.

AI-Driven Diabetic Retinopathy Screening Market Share Analysis By Segments, 2025 (%)

By Technology

Deep Learning & CNN led the market with 62.00% share in 2025, followed by Machine Learning at 20.00%, Hybrid AI Models at 13.00%, and Generative AI at 5.00%.

By Disease Severity

Mild NPDR accounted for 31.00% in 2025, followed by Moderate NPDR at 27.00%, Diabetic Macular Edema at 18.00%, Severe NPDR at 13.00%, and Proliferative DR at 11.00%.

By Product Type

Software Platforms dominated with 54.00% share in 2025, followed by Integrated Hardware & Software Devices at 31.00% and Standalone AI Cameras at 15.00%.

By End Use

Hospitals & Specialty Eye Clinics held the largest share at 38.00% in 2025, followed by Diabetes Care Centers & Endocrinology Clinics at 24.00%, Primary Care Clinics at 20.00%, Diagnostic & Imaging Centers at 10.00%, and Community & Teleophthalmology Programs at 8.00%.

Market Regional Insights:

AI-Driven Diabetic Retinopathy Screening Market Regional Share Analysis and Forecast, 2022–2025–2032

North America AI-Driven Diabetic Retinopathy Screening Market:

North America AI-driven diabetic retinopathy screening market held the largest share of 35.80% of the global market in 2025 and was valued at approximately USD 162.9 million. The regional market is primarily driven by the strong presence of leading AI diagnostics companies, high healthcare expenditure, widespread adoption of electronic medical records, and the regulatory clearance of autonomous AI screening systems by the FDA.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 North America Market Size: USD 162.9 Million
• 2035 North America Market Size: USD 450 Million
• CAGR (2026-2035): 10.70%

Drivers

• Strong adoption of FDA-cleared autonomous AI diagnostic systems for DR screening
• Presence of advanced healthcare and ophthalmic imaging infrastructure
• Increasing prevalence of Type 2 diabetes in the U.S. and Canada
• High investment in digital health and AI ophthalmology R&D

Restraints

• Inconsistent insurance reimbursement for AI-assisted ophthalmic screening
• Stringent FDA regulatory requirements for AI software as a medical device
• Algorithmic bias concerns in underrepresented minority patient populations
• High cost of advanced fundus imaging hardware integration

Opportunities

• Expansion of AI screening within primary care and endocrinology clinics
• Growing deployment across federally qualified health centers (FQHCs)

United States AI-Driven Diabetic Retinopathy Screening Market:

The U.S. accounted for the dominant share within North America and represented approximately 87.50% of the regional market in 2025. The U.S. AI-driven diabetic retinopathy screening market was valued at nearly USD 142.5 million, supported by the landmark FDA De Novo authorization of the IDx-DR autonomous AI system and large-scale deployment within integrated health systems and teleophthalmology networks.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 US Market Size: USD 142.5 Million
• 2035 US Market Size: USD 387 Million
• CAGR (2026-2035): 10.50%

Drivers

• First-mover regulatory framework with FDA autonomous AI diagnostic approvals
• High adoption of EHR-integrated AI screening platforms in major health systems
• Significant NIH and private investment in AI ophthalmology research
• Growing demand for remote diabetic eye screening via telehealth platforms

Restraints

• Regulatory pathway complexity for AI software updates and model iterations
• High liability concerns for autonomous AI diagnostic decisions
• Disparate access to screening in rural and low-income communities
• Data interoperability challenges with legacy EHR systems

Opportunities

• AI-integrated portable screening devices for community health deployment
• Expansion into multi-disease AI eye screening platforms

Canada AI-Driven Diabetic Retinopathy Screening Market:

Canada represented approximately 12.50% of the North American market in 2025 and was valued at around USD 20.4 million. The market is witnessing steady growth driven by increasing government investment in diabetic eye screening programs, provincial telehealth initiatives, and growing awareness regarding preventable diabetes-related blindness.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Canada Market Size: USD 20.4 Million
• 2035 Canada Market Size: USD 63 Million
• CAGR (2026-2035): 11.96%

Drivers

• Growing federal investment in digital health and AI diagnostic technologies
• Increasing provincial diabetic screening programs leveraging AI platforms
• Expanding aging population with high diabetes prevalence
• Rising adoption of teleophthalmology in remote and rural communities

Restraints

• High dependency on imported AI screening platforms and fundus cameras
• Limited reimbursement clarity for AI-based diagnostic services under provincial plans
• Budgetary constraints in public healthcare systems
• Delayed Health Canada approval pathways for AI software medical devices

Opportunities

• Expansion of decentralized diabetic retinopathy screening in community pharmacies
• Growing adoption of portable AI-integrated fundus cameras in primary care

Europe AI-Driven Diabetic Retinopathy Screening Market:

Europe accounted for approximately 26.50% of the global AI-driven diabetic retinopathy screening market in 2025 and was valued at nearly USD 120.6 million. The market benefits from established national diabetic eye screening programs in the UK, Germany, and Nordic countries, along with strong regulatory standards under the EU AI Act and EU MDR framework.

Market Intelligence Overview (Historical, Current, Forecast):

• 2025 Europe Market Size: USD 120.6 Million
• 2035 Europe Market Size: USD 336.7 Million
• CAGR (2026-2035): 0.82%

Drivers

• Established national diabetic eye screening programs integrated with AI grading systems
• Strong public healthcare reimbursement supporting AI-enabled screening deployment
• Growing elderly and diabetic population across Western and Southern Europe
• Increasing focus on preventive ophthalmology and early disease detection

Restraints

• Complex compliance requirements under EU Medical Device Regulation (MDR) and EU AI Act
• High operational costs for AI system deployment and clinical validation
• Limited AI screening reimbursement frameworks in Southern and Eastern Europe
• Market saturation in mature screening programs in Northern Europe

Opportunities

• Expansion of AI-graded screening platforms within national health service programs
• Rising investment in real-world evidence generation for AI diagnostic tools
• Increasing AI integration in diabetic macular edema detection

AI-Driven Diabetic Retinopathy Screening Market Key Players:

• Digital Diagnostics – 17.00%
• Eyenuk – 15.5%
• AEYE Health – 11.5%
• Retinalyze – 6.0%
• EyRIS – 5.0%
• Others
• Google Health
• Topcon Healthcare
• Optomed
• Canon Medical Systems
• NVIDIA
• IBM
• Medios Technologies
• Remidio Innovative Solutions
• Visulytix
• IDx Technologies
• iCare Health Solutions
• Airdoc
• Intelligent Retinal Imaging Systems (IRIS)
• RETINA-AI Health
• RetinaLyze System
• EyRIS
• VUNO
• Forus Health
• Evolucare
• Bosch Healthcare Solutions
• Carl Zeiss Meditec
• Heidelberg Engineering
• NIDEK
• Kowa
• Identifeye HEALTH
• Visionix
• MONA.health
• RetinaRisk
• BeamMed
• VoxelCloud
• Zhiyuan Huitu
• Zhenhealth
• Altris AI
• Annexa
• Retinal AI
• Voxeleron
• HEART EYE
• Siemens Healthineers
• Alibaba Health
• Tencent Healthcare
• Roche Diagnostics
• Microsoft
• RetinaLyze
• Thirona
• VisionQuest Biomedical
• Xtend.AI

AI-Driven Diabetic Retinopathy Screening Market Recent Developments

In March 2025, Digital Diagnostics (formerly IDx Technologies) announced the commercial expansion of its LumineticsCore AI retinal screening system to over 3,000 primary care and endocrinology clinics across the United States. The platform autonomously grades fundus images for diabetic retinopathy without the need for an ophthalmologist, enabling point-of-care detection within minutes. This deployment reflects the accelerating integration of autonomous AI diagnostic tools within mainstream diabetes management pathways and underscores the growing demand for scalable, AI-enabled ophthalmic screening solutions at the primary care level.

In January 2025, Google Health published clinical validation results for its Automated Retinal Disease Assessment (ARDA) AI system in The Lancet Digital Health, demonstrating 91.2% sensitivity and 95.7% specificity for referable diabetic retinopathy detection across a multi-ethnic patient cohort in India, Thailand, and the United States. The publication strengthens the clinical evidence base for AI-driven screening and supports regulatory submissions across Asia Pacific markets. It also highlights the ability of advanced deep learning systems to perform equitably across diverse racial and demographic groups, addressing a key concern among regulators and clinicians.

In May 2025, Topcon Corporation launched the Topcon AI Retinal Analysis Platform (TARAP) integrated within its Maestro2 fundus camera system, enabling simultaneous AI-assisted detection of diabetic retinopathy, age-related macular degeneration, and glaucoma suspect lesions in a single imaging session. This multi-pathology AI screening capability represents a significant advancement in the clinical utility and economic value proposition of AI-integrated ophthalmic imaging platforms. Topcon's partnership with leading EHR vendors for seamless workflow integration further positions the platform for broad adoption across hospital ophthalmology departments and community screening programs.

In September 2024, Retina-AI Health Inc. received CE marking under EU MDR for its cloud-based SightRisk AI platform for diabetic retinopathy and diabetic macular edema grading, enabling commercial deployment across European Union member states. The platform's regulatory clearance followed a prospective clinical evaluation across five European diabetic eye screening programs, demonstrating non-inferiority to human graders. This approval facilitates expanded market access in Europe and positions Retina-AI Health as a key competitor in the growing EU AI-enabled ophthalmology diagnostics segment.

AI-Driven Diabetic Retinopathy Screening Market Regulatory Landscape:

• FDA / EMA / PMDA approvals
• Fast Track / Breakthrough Device / De Novo authorization analysis
• Compliance framework overview under EU AI Act and EU MDR
• Regulatory impact assessment

AI-Driven Diabetic Retinopathy Screening Market Patent & IP Landscape

• Patent expiry analysis
• IP competitiveness
• Licensing agreements
• Innovation clusters

AI-Driven Diabetic Retinopathy Screening Market Segmentations:

Our research framework strategically segments the AI-driven diabetic retinopathy screening market by technology, disease severity, product type, end-user categories, and key regional markets.

By Technology

• Deep Learning & Convolutional Neural Networks (CNN)
• Machine Learning Algorithms
• Generative AI & Foundation Models
• Hybrid AI Models
• Others

By Disease Severity

• Mild Non-Proliferative Diabetic Retinopathy (NPDR)
• Moderate NPDR
• Severe NPDR
• Proliferative Diabetic Retinopathy (PDR)
• Diabetic Macular Edema (DME)
• Others

By Product Type

• AI Software Platforms (Cloud-Based, On-Premise)
• Integrated AI Hardware & Software Devices
• Standalone AI-Integrated Fundus Cameras
• Smartphone-Based AI Screening Systems

By End Use

• Hospitals & Ophthalmology Clinics
• Primary Care & Diabetes Management Centers
• Teleophthalmology Platforms
• Community Health Programs

By Region & Country

North America

• U.S.
• Canada

Europe

• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Rest of EU

Asia Pacific

• China
• India
• Japan
• Australia
• South Korea
• Thailand
• Rest of APAC

Latin America

• Brazil
• Argentina
• Mexico
• Rest of LA

Middle East & Africa

• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Rest of MEA